Faithward Advisors LLC Invests $3.52 Million in Natera, Inc. $NTRA

Faithward Advisors LLC purchased a new stake in Natera, Inc. (NASDAQ:NTRA) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 21,843 shares of the medical research company’s stock, valued at approximately $3,516,000.

A number of other institutional investors also recently modified their holdings of the business. Siemens Fonds Invest GmbH lifted its holdings in Natera by 3.1% in the 3rd quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock worth $290,000 after buying an additional 54 shares during the period. BOKF NA increased its stake in shares of Natera by 1.9% during the third quarter. BOKF NA now owns 3,733 shares of the medical research company’s stock valued at $601,000 after buying an additional 69 shares during the period. Silvant Capital Management LLC increased its stake in shares of Natera by 0.5% during the third quarter. Silvant Capital Management LLC now owns 13,488 shares of the medical research company’s stock valued at $2,171,000 after buying an additional 70 shares during the period. Main Management ETF Advisors LLC raised its holdings in shares of Natera by 1.7% during the second quarter. Main Management ETF Advisors LLC now owns 4,398 shares of the medical research company’s stock valued at $743,000 after acquiring an additional 72 shares in the last quarter. Finally, Yousif Capital Management LLC raised its holdings in shares of Natera by 4.5% during the third quarter. Yousif Capital Management LLC now owns 1,682 shares of the medical research company’s stock valued at $271,000 after acquiring an additional 72 shares in the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Solomon Moshkevich sold 915 shares of the company’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $204.13, for a total value of $186,778.95. Following the transaction, the insider owned 150,882 shares in the company, valued at $30,799,542.66. The trade was a 0.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider John Fesko sold 707 shares of the stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $204.13, for a total transaction of $144,319.91. Following the sale, the insider directly owned 189,199 shares in the company, valued at $38,621,191.87. This trade represents a 0.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 318,344 shares of company stock valued at $74,091,416. Insiders own 5.63% of the company’s stock.

Natera Stock Up 0.4%

Shares of NTRA opened at $198.38 on Wednesday. The stock has a market cap of $28.12 billion, a P/E ratio of -129.66 and a beta of 1.65. The business’s 50 day moving average price is $217.92 and its 200-day moving average price is $207.15. Natera, Inc. has a 52 week low of $125.38 and a 52 week high of $256.36.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.81. The company had revenue of $665.50 million during the quarter, compared to analyst estimates of $600.68 million. Natera had a negative return on equity of 15.28% and a negative net margin of 9.03%.During the same quarter last year, the company earned ($0.41) EPS. On average, equities analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Wells Fargo & Company lifted their price target on shares of Natera from $205.00 to $215.00 and gave the company an “equal weight” rating in a report on Friday, February 27th. Barclays upped their price objective on shares of Natera from $230.00 to $270.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Wall Street Zen raised shares of Natera from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. JPMorgan Chase & Co. boosted their price target on shares of Natera from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Finally, TD Cowen reissued a “buy” rating on shares of Natera in a research note on Wednesday, January 7th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $253.47.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.